Press Releases

Month Year

Month Year

Sep 28, 2021

New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection

Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza
Sep 19, 2021

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

*Phase 3 trial met its primary and key secondary endpoints
Sep 9, 2021

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Aug 30, 2021

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
Aug 6, 2021

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile

Show per page

Print
Email page
RSS